Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6919952 | 0.80 | IDO1 (0.51) | ALDH1A1MEN1KMT2AIDO1 | |
| SCHEMBL711731 | 0.79 | IDO1 (0.50) | ALDH1A1MEN1KMT2AIDO1 | |
| SCHEMBL7108734 | 0.79 | EPHX2 (0.57) | EPHX2HTR2CHTR2B | |
| SCHEMBL27988801 | 0.78 | IDO1 (0.53) | ALDH1A1EPHX2MEN1KMT2AIDO1 | |
| SCHEMBL6921464 | 0.78 | IDO1 (0.50) | ALDH1A1MEN1KMT2AIDO1 | |
| SCHEMBL13167894 | 0.77 | IDO1 (0.47) | ALDH1A1MEN1KMT2AIDO1 | |
| SCHEMBL17643567 | 0.77 | IDO1 (0.50) | ALDH1A1MEN1KMT2AIDO1 | |
| SCHEMBL7241601 | 0.77 | F2 (0.41) | ALDH1A1EPHX2 | |
| SCHEMBL23997640 | 0.76 | IDO1 (0.52) | ALDH1A1EPHX2MEN1KMT2AIDO1 | |
| SCHEMBL30079765 | 0.76 | IDO1 (0.52) | ALDH1A1MEN1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6528503-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| US-20030013700-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013700-A1 | Thrombin inhibitors | TFPI, PLAT, TFPI2 | ALDH1A1 2961/4885EPHX2 1735/4885CYP2C9 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.